The recent discovery of a coding mutation on the APP gene (A673T) which provides significant protection against cognitive decline in both AD patients as well as normal elderly individuals [54] is strong proof of the principle evidence that reducing Aβ levels is an effective therapeutic approach for AD. The gene discussed is APP; the disease is Mental deterioration.